Key Points
- CEO Ivor Elrifi bought 667,000 Tiziana Life Sciences shares at $1.00 each, investing $667,000 and increasing his direct ownership by 17.53% to 4.47 million shares.
- TLSA shares were trading at $0.99, up 2.3%, but remained below both the 50-day moving average of $1.15 and the 200-day average of $1.30.
- Analyst sentiment remained negative overall, with ratings spanning “hold” and “sell” and an average MarketBeat rating of “Reduce.”
Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) CEO Ivor Elrifi acquired 667,000 shares of the business's stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $1.00 per share, for a total transaction of $667,000.00. Following the completion of the acquisition, the chief executive officer directly owned 4,472,261 shares in the company, valued at approximately $4,472,261. The trade was a 17.53% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Tiziana Life Sciences Trading Up 2.3%
NASDAQ TLSA opened at $0.99 on Thursday. Tiziana Life Sciences Ltd has a 1 year low of $0.87 and a 1 year high of $2.53. The company has a fifty day moving average price of $1.15 and a 200-day moving average price of $1.30.
Hedge Funds Weigh In On Tiziana Life Sciences
Institutional investors have recently added to or reduced their stakes in the stock. Zhang Financial LLC boosted its stake in Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company's stock valued at $131,000 after acquiring an additional 12,000 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company's stock worth $420,000 after purchasing an additional 14,005 shares during the last quarter. Rachor Investment Advisory Services LLC bought a new stake in shares of Tiziana Life Sciences in the 4th quarter worth approximately $25,000. Cubist Systematic Strategies LLC bought a new stake in shares of Tiziana Life Sciences in the 1st quarter worth approximately $25,000. Finally, HRT Financial LP bought a new stake in shares of Tiziana Life Sciences in the fourth quarter valued at $36,000.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Tiziana Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, April 18th. Zacks Research raised shares of Tiziana Life Sciences to a "hold" rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings lowered Tiziana Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, May 29th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce".
Check Out Our Latest Research Report on TLSA
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.
The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
